Sunday, September 21, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Stocks

Pfizer Stock: Morgan Stanley Raises Target Amid Strong Earnings

Felix Baarz by Felix Baarz
August 6, 2025
in Stocks
0
Pfizer Stock
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Pfizer’s stock received a boost as Morgan Stanley raised its price target from $32 to $33, reflecting optimism after the pharmaceutical giant reported better-than-expected Q2 results. Adjusted earnings surged 20% year-over-year to $9.6 billion, while revenue grew modestly to $28.4 billion. The company outperformed analyst estimates with Q2 earnings of $0.78 per share, 37% above projections, and revenue of $14.7 billion versus $13.47 billion expected. Management also raised its full-year adjusted EPS guidance to $2.90–$3.10, citing cost-cutting measures and strong performance from drugs like Eliquis and Xeljanz.

Regulatory Risks Loom Despite Growth

While Pfizer’s fundamentals remain strong, regulatory challenges cast a shadow. Potential U.S. tariffs of up to 250% on drug imports and government-mandated price cuts threaten profitability. The company has factored these risks into its 2025 outlook, but investor sentiment remains mixed. Shares rose 5% post-announcement, trading at $24.50, significantly outpacing the S&P 500. Analysts note the stock’s recovery from pandemic lows but caution that regulatory decisions could dictate its future trajectory.

Ad

Pfizer Stock: Buy or Sell?! New Pfizer Analysis from September 21 delivers the answer:

The latest Pfizer figures speak for themselves: Urgent action needed for Pfizer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 21.

Pfizer: Buy or sell? Read more here...

Tags: Pfizer
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Quantum Computing Stock
Stocks

Quantum Computing Stock Dips Despite Major Contract Wins

September 16, 2025
Coinbase Stock
Stocks

Institutional Partnership Fuels Optimism for Coinbase’s Future

September 16, 2025
Strategy Stock
Stocks

MicroStrategy’s Bitcoin Bet Faces Market Skepticism

September 16, 2025
Next Post
Uber Stock

Uber Stock: Strong Earnings Met With Market Skepticism

LifeMD Stock

LifeMD Stock: Plunge Amidst Earnings Shock and Growth Concerns

AMD Stock

AMD Stock: Mixed Results Amid China Export Woes

Recommended

Babcock & Wilcox Enterprises Stock

Strategic Debt Moves Fuel Investor Confidence in Babcock & Wilcox

3 weeks ago
FLO stock news

Analysts Evaluation and Price Targets for KimberlyClark Stock March 1 2024

2 years ago
DrugRetailers Stock Exchange

Analysts Bullish on Academy Sports with Strong Buy Consensus

2 years ago
Biotechnology Trading online

Leonardo DRS Exceeds Expectations with Impressive FourthQuarter 2023 Results

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

AAPL Adobe Alibaba Alphabet Amazon AMD AMZN Apple ASML BA BigBear.ai BioNTech Broadcom Coinbase Eli Lilly Fiserv Hims & Hers IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Opendoor Oracle Oxford Lane Capital Palantir Pepsi Red Cat Robinhood Rocket Lab USA Salesforce Strategy Tesla Tilray TSLA Unitedhealth Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Market Confidence Wanes as Leggett & Platt Faces Mounting Headwinds

Semiconductor Stock Faces Diverging Signals as Insiders Sell Amid Institutional Buying

Micron Technology’s AI-Driven Rally Faces Critical Earnings Test

Institutional Confidence Meets Insider Caution at Barrett Business Services

Healthcare Tech Firm Phreesia Stuns Market with First-Ever Quarterly Profit

Legal Inquiry Casts Shadow Over Extreme Networks’ Strong Performance

Trending

Ezcorp Stock
Analysis

Institutional Investors Clash with Insider Over Ezcorp’s Direction

by Robert Sasse
September 21, 2025
0

A fascinating divergence in investment strategy is unfolding around Ezcorp Inc., pitting a company director against a...

Pepsi Stock

PepsiCo’s Multi-Billion Dollar Debt Strategy Divides Market Opinion

September 21, 2025
Carter's Stock

Institutional Investors Make Significant Moves in Carter’s Stock

September 21, 2025
Leggett & Platt Stock

Market Confidence Wanes as Leggett & Platt Faces Mounting Headwinds

September 21, 2025
MaxLinear Stock

Semiconductor Stock Faces Diverging Signals as Insiders Sell Amid Institutional Buying

September 21, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Institutional Investors Clash with Insider Over Ezcorp’s Direction
  • PepsiCo’s Multi-Billion Dollar Debt Strategy Divides Market Opinion
  • Institutional Investors Make Significant Moves in Carter’s Stock

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com